LabGenius Debuts T-cell Engager Optimisation Capability That Yields Molecules with >400-fold Tumour Killing Selectivity Versus Clinical Benchmark
LabGenius Appoints Prof Hendrik-Tobias Arkenau and Prof Victor Greiff as Scientific Advisors.
Emily Brady from Obvious Ventures highlights LabGenius' big bold mission to accelerate the AI search for protein therapeutics.
Get to know LabGenius' CTO, Ex-Rahko co-founder & CEO and former VP of AI Odyssey Therapeutics, Dr Leonard Wossnig.
LabGenius Wins Government Innovation Grant To Support The Development Of ML-driven Cancer Therapies
Q&A with Dr. Catherine Howsham, Scientific Project Manager
LabGenius Appoints Dr. Leonard Wossnig as Chief Technology Officer
LabGenius Secures Government Innovation Grant to Expand ML-driven Drug Discovery Platform, EVA™
Q&A with Justin Grace, Senior Data Scientist @ LabGenius
The group shared their perspectives to surface the challenges being faced by TechBio companies using machine learning to accelerate drug discovery
Founder & CEO, James Field, will be discussing the opportunities and challenges faced when ‘Scaling as a Founder’ at this year's Sifted Summit
Founder & CEO, James Field, explains how LabGenius is combining human and machine intelligence to accelerate research into advanced medicines
Ex-Google CFO and LabGenius Investor, Patrick Pichette, shares his advice for scaling with efficiency
Q&A with Dr. Dan Foxler, Principal Scientist @ LabGenius
LabGenius is attending the BIO-Europe Spring partnering conference
LabGenius recognized by Sifted as a drug discovery startup to watch
Data Science Lead, Katya Putintseva, presented at The Antibody Engineering & Therapeutics conference
Founder and CEO, James Field, took part in the BIOS Community Spotlight Series
LabGenius appoints Dr. Gino Van Heeke as Chief Scientific Officer
LabGenius presents a scientific poster at drug discovery conference, Discovery UK
